Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 18, 2024

Primary Completion Date

September 3, 2025

Study Completion Date

September 9, 2025

Conditions
Parkinson Disease
Interventions
DRUG

TJ0113

200 mg or 400 mg Capsule, Once Daily

DRUG

Placebo

Capsule, Once Daily

Trial Locations (1)

310009

Second Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou

All Listed Sponsors
collaborator

Taizhou Hospital

OTHER

collaborator

Wenzhou Central Hospital

OTHER

collaborator

Sir Run Run Shaw Hospital

OTHER

collaborator

The Second Affiliated Hospital of Jiaxing University

OTHER

collaborator

Hangzhou PhecdaMed Co., Ltd.

INDUSTRY

collaborator

Huzhou Central Hospital

OTHER

collaborator

Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

OTHER

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT06596005 - Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease | Biotech Hunter | Biotech Hunter